Supplements
Saffron: culinary stigmas versus extracts, low mood and clinical depression, conflicting outcome scales, newer trials, and safety limits
On this page
What is being compared?
| Term | Meaning |
|---|---|
| Stigma | The flower material used to produce saffron.[2] |
| Standardized extract | A preparation characterized by selected constituents; it is not automatically equivalent to another extract.[4] |
| Crocin | A saffron constituent studied separately from a whole preparation.[6] |
| Subclinical symptoms | Symptoms in a study population that do not establish the same eligibility as diagnosed major depression.[2] |
| BDI and BAI | Self-report depression and anxiety questionnaires used in the review.[1] |
The larger 2025 study enrolled people with low mood
A twelve-week placebo-controlled study enrolled 202 adults with subclinical depressive symptoms. Its prespecified depression questionnaire comparison favored the selected extract. Most other secondary comparisons showed no evidence of a difference; a sleep finding concerned an exploratory subgroup. This result should retain both its primary success and its secondary limitations.[2]
Eligibility limits the interpretation
No serious adverse events were reported. Long-term relapse prevention, other diagnoses and sponsor roles remain unestablished here.[2]
A newer 2026 formulation study falls after the review search
The newer trial randomized 56 participants with low mood or subclinical-to-mild symptoms. It reported favorable mood findings over eight weeks. The indexed original report describes a standardized formulation, homogeneous population and last-observation-carried-forward handling of missing outcomes. A later publication belongs beside, rather than silently inside, a July 2025 search.[4]
Standardization is useful information, not a universal guarantee
The report cautions that low baseline variability can affect standardized effect estimates. Full attrition, prespecification, patent and sponsor-role appraisal remain pending. Neither this formulation nor a later positive mood result establishes prevention of clinical depression, equivalence to antidepressants or interchangeability with kitchen saffron.[4]
A one-week safety study found laboratory changes
The 2008 safety experiment studied thirty healthy volunteers for seven days. It found no gross clinical changes, but reported blood-pressure and selected blood-count and biochemical changes. The authors considered the observed laboratory alterations within normal ranges and not clinically important in that experiment. This is a narrower conclusion than saying saffron never changes laboratory measurements.[5]
Short observation cannot answer lifetime or special-population questions
Ten participants per group and one week cannot characterize uncommon harms, chronic exposure, pregnancy or all medicine combinations. Its historical study doses are exposures under investigation, rather than a recommended self-treatment regimen. Safety evidence should retain the exact preparation, participant selection and observation period.[5]
An isolated-constituent study is a different safety experiment
A small month-long trial assigned 44 healthy volunteers to crocin or placebo. It reported no major adverse events and changes in selected laboratory measures. Its conclusion was limited to the studied conditions. Crocin safety cannot be assigned automatically to a whole extract, another constituent or every botanical product bearing the word saffron.[6]
Safety and mood efficacy need separate evidence
A healthy-volunteer constituent experiment does not demonstrate treatment of depression. It also does not establish reproductive safety, protection against interactions or adequate monitoring for someone with an existing condition. Longer, independently appraised studies and product-specific evidence remain relevant unanswered questions.[6]
Evidence & uncertainty
A 2026 review found improvements on some self-reported depression and anxiety scales, with substantial inconsistency, but not on several other scales. Trials in people with subclinical low mood should be distinguished from trials in diagnosed depressive disorders. A positive questionnaire result is not permission to replace existing mental-health care.[1][2]
Selected-source overview · Independent review pendingPublished questions
Is a saffron stigma, whole extract and isolated crocin the same preparation?
Selected-source overview · Independent review pending. Read the evidence context.
Their composition and study exposures differ.[6]
Evidence behind this answer
- Safety evaluation of crocin tablets in healthy volunteers
randomized safety trial · 2013
Original indexed abstract and selected original result passages inspected; no independent full-text appraisal · Original indexed full abstract: 44 healthy volunteers, one month and selected laboratory changes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the 2026 saffron review significantly improve every depression and anxiety scale?
Selected-source overview · Independent review pending. Read the evidence context.
Some pooled scales were nonsignificant.[1]
Evidence behind this answer
- Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed review of 34 trials
systematic review · 2026
Original review summary and selected methods/results inspected; no independent full-text appraisal · Original full abstract: July 2025 search, 34 trials, 1,769 adults and differing outcome-scale findings
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the saffron review search include all later 2026 studies?
Selected-source overview · Independent review pending. Read the evidence context.
Its search ended in July 2025.[1]
Evidence behind this answer
- Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed review of 34 trials
systematic review · 2026
Original review summary and selected methods/results inspected; no independent full-text appraisal · Original full abstract: July 2025 search, 34 trials, 1,769 adults and differing outcome-scale findings
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the 2025 Affron study establish treatment for every diagnosed depressive disorder?
Selected-source overview · Independent review pending. Read the evidence context.
It enrolled adults with subclinical symptoms.[2]
Evidence behind this answer
- Saffron extract and mood and general wellbeing in adults experiencing low mood
randomized trial · 2025
Original indexed abstract and selected original result passages inspected; no independent full-text appraisal · 2025 original indexed full abstract: 202 adults, twelve weeks, primary depression score and secondary/subgroup boundaries
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did every secondary outcome in the 2025 saffron study favor the extract?
Selected-source overview · Independent review pending. Read the evidence context.
Most secondary comparisons did not.[2]
Evidence behind this answer
- Saffron extract and mood and general wellbeing in adults experiencing low mood
randomized trial · 2025
Original indexed abstract and selected original result passages inspected; no independent full-text appraisal · 2025 original indexed full abstract: 202 adults, twelve weeks, primary depression score and secondary/subgroup boundaries
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is the 2005 saffron trial an independent extra replication whenever a later review cites it?
Selected-source overview · Independent review pending. Read the evidence context.
The underlying trial remains the same experiment.[3]
Evidence behind this answer
- Crocus sativus in mild-to-moderate depression: placebo-controlled trial
randomized trial · 2005
Original indexed abstract and selected original result passages inspected; no independent full-text appraisal · 2005 original indexed full abstract: forty outpatients, six weeks and Hamilton depression ratings
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can a later saffron formulation study be assumed part of an earlier search cutoff?
Selected-source overview · Independent review pending. Read the evidence context.
Publication and search dates must be distinguished.[4]
Evidence behind this answer
- Standardized saffron extract formulation for low mood and subclinical depressive symptoms
randomized trial · 2026
Selected original indexed methods/results passages inspected, including participant disposition in turn2287search0; direct full-text retrieval blocked, complete trial appraisal pending · 2026 selected indexed original methods/results: 56 randomized, eight weeks, formulation, missing-data method and effect-size caution
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the one-week saffron safety experiment show no laboratory changes?
Selected-source overview · Independent review pending. Read the evidence context.
It reported selected changes within normal ranges.[5]
Evidence behind this answer
- Safety evaluation of saffron tablets in healthy volunteers
randomized safety trial · 2008
Original full abstract inspected; full methods, individual harms and long-term safety appraisal pending · 2008 original full abstract: thirty volunteers, one week and selected hemodynamic/laboratory changes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
The 2026 synthesis did not find a uniform result
The review included 34 randomized trials with 1,769 adults, searching through July 2025. Pooled BDI and BAI scores favored saffron, with very high heterogeneity. Hamilton depression and anxiety ratings and Profile of Mood States comparisons were nonsignificant. The abstract reports moderate GRADE certainty; full outcome-specific grading appraisal is pending.[1]
Different scales and trial sets can yield different answers
These results do not show that every self-report instrument improves or that clinician assessments always fail. Each analysis uses eligible studies and a particular outcome. Product differences, trial overlap and inconsistency matter. A reference count is not a count of independent replications, and the Atlas has not conducted its own formal GRADE assessment.[1]
An early clinical-depression trial was small and brief
The 2005 placebo-controlled trial studied forty outpatients with mild-to-moderate depression for six weeks. Hamilton depression scores favored saffron. Observed side effects did not differ significantly. The authors called for larger trials; this small study cannot establish equal safety or settle the entire later evidence base.[3]
An early positive trial and a later pooled null result can coexist
A selected positive study and a nonsignificant pooled comparison are not interchangeable. The synthesis may include different studies, preparations and populations, including the earlier experiment itself. Explaining the discrepancy requires full trial-level reconciliation rather than choosing the most favorable headline or counting the same participants twice.[3]
References
- Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed review of 34 trials
Systematic review
Original review authors · Content/publication date: 2026
Accessed: 2026-10-09 UTC · Original review summary and selected methods/results inspected; no independent full-text appraisal
Cited sections: Original full abstract: July 2025 search, 34 trials, 1,769 adults and differing outcome-scale findings - Saffron extract and mood and general wellbeing in adults experiencing low mood
Randomized trial
Original trial authors · Content/publication date: 2025
Accessed: 2026-10-09 UTC · Original indexed abstract and selected original result passages inspected; no independent full-text appraisal
Cited sections: 2025 original indexed full abstract: 202 adults, twelve weeks, primary depression score and secondary/subgroup boundaries - Crocus sativus in mild-to-moderate depression: placebo-controlled trial
Randomized trial
Original trial authors · Content/publication date: 2005
Accessed: 2026-10-09 UTC · Original indexed abstract and selected original result passages inspected; no independent full-text appraisal
Cited sections: 2005 original indexed full abstract: forty outpatients, six weeks and Hamilton depression ratings - Standardized saffron extract formulation for low mood and subclinical depressive symptoms
Randomized trial
Original trial authors · Content/publication date: 2026
Accessed: 2026-10-09 UTC · Selected original indexed methods/results passages inspected, including participant disposition in turn2287search0; direct full-text retrieval blocked, complete trial appraisal pending
Cited sections: 2026 selected indexed original methods/results: 56 randomized, eight weeks, formulation, missing-data method and effect-size caution - Safety evaluation of saffron tablets in healthy volunteers
Randomized safety trial
Original safety trial authors · Content/publication date: 2008
Accessed: 2026-10-09 UTC · Original full abstract inspected; full methods, individual harms and long-term safety appraisal pending
Cited sections: 2008 original full abstract: thirty volunteers, one week and selected hemodynamic/laboratory changes - Safety evaluation of crocin tablets in healthy volunteers
Randomized safety trial
Original safety trial authors · Content/publication date: 2013
Accessed: 2026-10-09 UTC · Original indexed abstract and selected original result passages inspected; no independent full-text appraisal
Cited sections: Original indexed full abstract: 44 healthy volunteers, one month and selected laboratory changes
Scope & review
- Population
- Readers exploring saffron; subclinical low mood, clinical-depression outpatients and healthy-volunteer safety experiments are distinguished
- Exposure or intervention
- Specific standardized saffron extracts, stigma preparations and isolated crocin versus placebo
- Comparison
- Source-specific symptom, care, screening or comparator settings
- Outcomes
- Self-report and clinician mood scales, exploratory sleep outcomes, adverse events and laboratory measurements
- Timeframe
- Short trials from 2005–2026; the 2026 synthesis searched through July 2025
- Jurisdiction
- Selected US agency sources, dated professional guidance and original international research; jurisdiction and eligibility are source-specific
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-09 UTC: Added a sourced explanation in a bounded ten-article batch; qualified review remains pending.
What this article still leaves open
- Full contemporary trial-level synthesis, scale-specific certainty, review overlap, attrition, prespecification and sponsor/patent appraisal remain outstanding.
- Comparisons with medicines, relapse prevention, other uses, adulteration, interactions, pregnancy, childhood and long-term safety need expansion.
- Qualified review, personal psychiatric assessment and saffron or antidepressant-treatment regimens are not supplied.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.